Lonza 4D or equal nucleofection system

The FDA's Center for Biologics Evaluation and Research intends to procure a Lonza 4D nucleofection system or equivalent, with a response deadline of July 8, 2026. This is a Sources Sought Notice (SSN) — a market survey for written information only and does not constitute a solicitation or obligate contract award.

The system will be installed at FDA/CBER in Silver Spring, Maryland (Building 52/72, Room 4107, 10903 New Hampshire Avenue, MD 20993-0002) within 120 days of contract award. The nucleofection system must deliver DNA, RNA, and proteins into cell lines (HEK293, CHO, Huh7) and human primary cells using conductive polymer (metal-free) electrodes, process 2×10⁴ to 1×10⁷ cells per reaction, achieve post-transfection cell viability up to 90%, and include factory-preprogrammed pulse protocols calibrated for primary human dendritic cells. The equipment must be newly manufactured and delivered as a turn-key solution with installation, training, and a one-year warranty.

The FDA targets small business concerns under NAICS 334516 (Analytical Laboratory Instrument Manufacturing, 1,000-employee size standard), though all interested parties are encouraged to respond. Domestic products are especially sought. Responses must include company information, past performance within the last three years, technical specifications, GSA Schedule and BIC contract information if applicable, place of manufacture for Buy American compliance, and informational pricing. Submit responses by email to Suzanne Martella (suzanne.martella@fda.hhs.gov) by 10:00 am Central Time on July 8, 2026, referencing 75F40126SSN134795. Responses with weblinks will not be opened; do not include proprietary information.